Kalayci D, Gürgey A, Güven D, Parlak H, Hasiripi H
Department of Ophthalmology, Ankara Numune Hospital, Turkey.
Acta Ophthalmol Scand. 1999 Dec;77(6):622-4. doi: 10.1034/j.1600-0420.1999.770602.x.
The role of factor V Leiden and prothrombin 20210 A mutations has been investigated in patients with central retinal vein occlusion (CRVO), hemispheric retinal vein occlusion (HRVO), and branch retinal vein occlusion (BRVO).
Factor V Leiden and prothrombin 20210 A were investigated in DNA obtained from the peripheral blood of 52 patients with retinal vein occlusion. Twenty-five of the patients had either CRVO or HRVO, and 27 patients had BRVO. The control groups for factor V Leiden and prothrombin 20210 A were comprised of two separate groups of 81 and 87 healthy individuals, respectively, who had been previously investigated for the mutations at Hacettepe University Department of Hematology. The frequencies of factor V Leiden and prothrombin 20210 A mutations were compared between the patients and the controls using Fisher's exact test.
Factor V Leiden mutation was found in 8% of all patients, 4% of the CRVO-HRVO group and 11% of the BRVO patients. Prothrombin 20210 A mutation was not found in any of the patients. Factor V Leiden and prothrombin 20210 A mutations have been previously found in 7% and 2% of the healthy controls, respectively. The differences of frequencies between the patients and the controls were not statistically significant.
Factor V Leiden and prothrombin 20210 A mutations have not been found to be risk factors in either type of retinal vein occlusion.
研究因子V莱顿突变和凝血酶原20210A突变在视网膜中央静脉阻塞（CRVO）、半侧视网膜静脉阻塞（HRVO）和视网膜分支静脉阻塞（BRVO）患者中的作用。
对52例视网膜静脉阻塞患者外周血DNA中的因子V莱顿突变和凝血酶原20210A突变进行研究。其中25例患者患有CRVO或HRVO，27例患者患有BRVO。因子V莱顿突变和凝血酶原20210A突变的对照组分别由两组独立的健康个体组成，每组分别有81例和87例，这些个体之前在哈杰泰佩大学血液学系接受过突变检测。采用Fisher精确检验比较患者组和对照组中因子V莱顿突变和凝血酶原20210A突变的频率。
在所有患者中，8%发现因子V莱顿突变，CRVO-HRVO组为4%，BRVO患者为11%。在所有患者中均未发现凝血酶原20210A突变。之前在健康对照组中分别发现7%的因子V莱顿突变和2%的凝血酶原20210A突变。患者组和对照组之间的频率差异无统计学意义。
未发现因子V莱顿突变和凝血酶原20210A突变是任何一种类型视网膜静脉阻塞的危险因素。
